Vitamin K Epoxide Reductases

• 

  Subject Areas on Research

  • A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. 
  • A pharmacogenetic versus a clinical algorithm for warfarin dosing. 
  • A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. 
  • Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses. 
  • Estimation of the warfarin dose with clinical and pharmacogenetic data. 
  • Genetic-based dosing in orthopedic patients beginning warfarin therapy. 
  • Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy. 
  • Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation. 
  • Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. 
  • The long and winding road to warfarin pharmacogenetic testing. 
  • Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. 
  • VKORC1 haplotypes in five East-Asian populations and Indians.